Weekly Psychedelic Policy Briefing: October 12, 2026
Research & History
Psychedelics Today

Weekly Psychedelic Policy Briefing: October 12, 2026

Psychedelics TodayOctober 12, 20261 min read
Curated by Paradise Farmers Market

FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling.

Compass Pathways executives discussed pricing as the COMP360 NDA nears completion, and state cannabis regulators say the DEA still hasn’t answered their rescheduling questions.

Read the full story

Continue reading at Psychedelics Today

Read Original

Originally reported by Psychedelics Today at Psychedelics Today

Paradise Farmers Market curates content for educational purposes.